|
Today's Headlines
Long-term use of nonsteroidal anti-inflammatory drugs following a first-time myocardial infarction is associated with persistent increased cardiovascular risk, according to an online study published September 24 in the journal Circulation. » Full article
|
|
Treatment with omega-3 polyunsaturated fatty acids to prevent cardiovascular disease (CVD) has been controversial. A recent meta-analysis and review showed that overall, omega-3 PUFA supplementation did not lower the risk of CVD, according to data published in the Sept. 12, 2012 issue of JAMA. » Full article
|
|
FDA has approved adalimumab (Humira, Abbott) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis when certain other medicines have not worked well enough. Combined with its approval to treat moderate-to-severe Crohn's disease, adalimumab is now approved for the treatment of the 2 primary diseases that comprise inflammatory bowel disease. » Full article
|
|
Tranexamic acid can safely be used in all trauma patients, not just those who are the most severely injured, according to data analyses results published in the September 11 issue of the British Medical Journal. » Full article
|
|
CONTINUING EDUCATION
Welcome to a new CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 CPE credits from September 2012-March 2013 with 7 monthly knowledge-based activities. This month, the professional development activity will cover the pathophysiology, diagnosis, screening, and risk factors associated with diabetes mellitus.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
|
|
EDITOR'S PICK
Irritable bowel syndrome (IBS) is prevalent, expensive to treat, and is associated with significantly impaired health-related quality of life and reduced productivity. This article reviews the current therapies, including probiotics, 5HT3 antagonists, 5HT4 agonists, antidepressants, and lubiprostone, with a focused appraisal of the role of rifaximin from a managed care perspective. Emerging agents are also discussed. » Full article
|
Survey
a) Hardly ever
b) Once a week
c) Once a month
d) Once a day
Respond here and see what your colleagues think too.Want to see the results of our last survey. Click here.
|
|
|
Like
Tweet
